scholarly journals North Central Cancer Treatment Group N0543 (Alliance): A phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma

Cancer ◽  
2017 ◽  
Vol 123 (18) ◽  
pp. 3494-3501 ◽  
Author(s):  
Robert R. McWilliams ◽  
Nathan R. Foster ◽  
Michelle R. Mahoney ◽  
Thomas C. Smyrk ◽  
Joseph A. Murray ◽  
...  
Keyword(s):  
Treatment Group ◽  
Small Bowel ◽  
Cancer Treatment ◽  
Small Bowel Adenocarcinoma ◽  
Phase 2 ◽  
First Line ◽  
North Central ◽  
First Line Therapy ◽  
Phase 2 Trial ◽  
Line Therapy

scholarly journals A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872

Cancer ◽  
2019 ◽  
Vol 125 (21) ◽  
pp. 3790-3800 ◽  
Author(s):  
Evanthia Galanis ◽  
S. Keith Anderson ◽  
Erin L. Twohy ◽  
Xiomara W. Carrero ◽  
Jesse G. Dixon ◽  
...  
Keyword(s):  
Treatment Group ◽  
Cancer Treatment ◽  
Phase 1 ◽  
Recurrent Glioblastoma ◽  
Phase 2 ◽  
North Central ◽  
Phase 2 Trial

Pharmacogenetic dosing by UGT1A1 genotype as first-line therapy for advanced small-bowel adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) trial.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 314-314 ◽  
Author(s):  
Robert R. McWilliams ◽  
Michelle R. Mahoney ◽  
Benjamin T. Marchello ◽  
Aminah Jatoi ◽  
Keith D. Krewer ◽  
...  
Keyword(s):  
Small Bowel ◽  
Small Bowel Adenocarcinoma ◽  
First Line ◽  
Prospective Data ◽  
North Central ◽  
First Line Therapy ◽  
Dosing Strategy ◽  
Prolonged Response ◽  
Ugt1a1 Genotype

314 Background: Small bowel adenocarcinoma (SB-ACA) is rare, having little prospective data guiding management. A prior phase I study evaluated UGT1A1 genotype specific dosing of oxaliplatin, irinotecan, and capecitabine. Our prospective, multicenter clinical trial assessing tumor response in pts having metastatic SB-ACA, used a similar dosing strategy. Methods: Genotypes were determined via central lab. Previously untreated pts were dosed by UGT1A1*28 genotypes 6/6, 6/7, and 7/7 receiving 100/85/85 mg/m2 oxaliplatin d1, 150/150/75 mg/m2 irinotecan d1, and 1600/400/200 mg/m2 capecitabine (BID) d2-15 of 21 days. The study design was such that 1 confirmed response in 16 pts expanded enrollment to 33 pts, with 7 required for demonstrating efficacy. Results: 28 pts (13-6/6, 10-6/7, 5-7/7) have been enrolled [75% male, mean age 62.5 (range 41-77)]. Location of primary included: duodenum (63%), jejunum (26%), and ileum (7%), with pts having >1 metastatic site (abdominal-41%, bone-7%, liver-56%, lung-30%, nodal-52%, subcutaneous-4%, other-19%). Gr 3+ treatment related toxicity was not significantly different by genotype (50%-6/6, 44%-6/7, 20%-7/7, p=0.48) and included (pts): diarrhea(5), vomiting(5), leukopenia(5), neutropenia(7), and nausea(6). 57% (13 of 23) pts achieved responses during therapy, with a confirmed response rate of 39% (95% CI 0-58%). 18 have died, with a median follow-up of 8.3 mos (range 0-43). Conclusions: UGT1A1 genotype directed dosing with oxaliplatin, irinotecan, and capecitabine appears to result in prolonged response in this population. Larger studies are needed to determine comparability to CapeOx alone or if response/toxicity differs among genotypes. Supported by NIH Grant CA25224, Sanofi-Aventis, and Pfizer. [Table: see text]

DISRUPT: A randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane–platinum regimen as first-line therapy for metastatic non-small cell lung cancer

Lung Cancer ◽  
2014 ◽  
Vol 85 (2) ◽  
pp. 224-229 ◽  
Author(s):  
Joachim von Pawel ◽  
Vera Gorbounova ◽  
Martin Reck ◽  
Dariusz M. Kowalski ◽  
Aurore Allard ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
First Line ◽  
First Line Therapy ◽  
Phase 2 Trial ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document